Britain and America have forged a major commercial pact that will preserve no tariffs on British pharmaceutical shipments being sold in the US market.
Key Provisions of the Deal
As part of the deal, the UK has committed to increase expenditure on drugs through the NHS. This move guarantees that tariffs on these key exports will remain at zero for a timeframe of the next three years.
This agreement is in response to previous warnings to hike tariffs on branded drug imports, with potential rates floated as high as one hundred percent.
"This agreement between the Britain strengthens the worldwide climate for cutting-edge drugs and introduces long-overdue equity to American-British drug exports," a release said.
Trade Importance
Drugs are one of the the United Kingdom's largest exports to the United States, which is clearly the biggest destination for large companies like GSK and AstraZeneca.
Statistics show that in the year prior to September, the UK exported medicines totaling £11.1bn to the US. This value made up nearly one-fifth of British export trade in that timeframe.
"This deal safeguards work, boosts capital expenditure and paves the way for the UK to become a global hub for life sciences," a government official stated.
Key NHS Changes
The pact involves several key commitments from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to double total health service expenditure on medicines from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The amount drug companies must return to the NHS to control costs will be limited at 15%. In the past, refunds exceeded twenty percent.
Industry Background
The pact comes amid a long-running row between the sector and the ministers over medicine costs and NHS adoption.
This friction were exacerbated by assertions that American consumers were paying several times more for the identical medicines than consumers in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been paused or abandoned, while major funding commitments have been pledged toward projects in the United States.
One official stated that the NHS needed to increase expenditure on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the previous ten-year period.
